Charles River Laboratories Common Stock Net 2010-2025 | CRL

Charles River Laboratories common stock net from 2010 to 2025. Common stock net can be defined as the value of common equity ownership.
  • Charles River Laboratories common stock net for the quarter ending June 30, 2025 was $0.001B, a 0.77% decline year-over-year.
  • Charles River Laboratories common stock net for 2024 was $0.001B, a 0.39% decline from 2023.
  • Charles River Laboratories common stock net for 2023 was $0.001B, a 0.79% increase from 2022.
  • Charles River Laboratories common stock net for 2022 was $0.001B, a 0.79% increase from 2021.
Charles River Laboratories Annual Common Stock Net
(Millions of US $)
2024 $1
2023 $1
2022 $1
2021 $1
2020 $0
2019 $0
2018 $0
2017 $1
2016 $1
2015 $1
2014 $1
2013 $1
2012 $1
2011 $1
2010 $1
2009 $1
Charles River Laboratories Quarterly Common Stock Net
(Millions of US $)
2025-06-30 $1
2025-03-31 $1
2024-12-31 $1
2024-09-30 $1
2024-06-30 $1
2024-03-31 $1
2023-12-31 $1
2023-09-30 $1
2023-06-30 $1
2023-03-31 $1
2022-12-31 $1
2022-09-30 $1
2022-06-30 $1
2022-03-31 $1
2021-12-31 $1
2021-09-30 $1
2021-06-30 $1
2021-03-31 $1
2020-12-31 $0
2020-09-30 $0
2020-06-30 $0
2020-03-31 $0
2019-12-31 $0
2019-09-30 $0
2019-06-30 $0
2019-03-31 $0
2018-12-31 $0
2018-09-30 $1
2018-06-30 $1
2018-03-31 $1
2017-12-31 $1
2017-09-30 $1
2017-06-30 $1
2017-03-31 $1
2016-12-31 $1
2016-09-30 $1
2016-06-30 $1
2016-03-31 $1
2015-12-31 $1
2015-09-30 $1
2015-06-30 $1
2015-03-31 $1
2014-12-31 $1
2014-09-30 $1
2014-06-30 $1
2014-03-31 $1
2013-12-31 $1
2013-09-30 $1
2013-06-30 $1
2013-03-31 $1
2012-12-31 $1
2012-09-30 $1
2012-06-30 $1
2012-03-31 $1
2011-12-31 $1
2011-09-30 $1
2011-06-30 $1
2011-03-31 $1
2010-12-31 $1
2010-09-30 $1
2010-06-30 $1
2010-03-31 $1
2009-12-31 $1
2009-09-30 $1
2009-06-30 $1
2009-03-31 $1
Sector Industry Market Cap Revenue
Medical Medical Services $8.012B $4.050B
Charles River Laboratories International, Inc. is a full service, early-stage contract research organization. The company provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions globally accelerate their research and drug development efforts. The company has a diverse portfolio of discovery and safety assessment services, both Good Laboratory Practice (GLP) and non-GLP. This helps support its clients from target identification through non-clinical development. Charles River also provides a line of products and services to support clients' manufacturing activities. Utilizing the company's broad portfolio of products and services, clients can create a more flexible drug development model, aiming cost reduction, productivity enhancement and increase in speed to market. Charles River currently has three reporting segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA) and Manufacturing Support.
Stock Name Country Market Cap PE Ratio
Danaher (DHR) United States $146.791B 27.22
CVS Health (CVS) United States $91.231B 11.35
Elevance Health (ELV) United States $69.762B 9.38
Cencora (COR) United States $56.333B 18.76
DiDi Global (DIDIY) China $26.403B 28.05
Labcorp Holdings (LH) United States $23.210B 18.45
Natera (NTRA) United States $22.377B 0.00
BioMerieux (BMXMF) France $17.423B 0.00
EUROFINS SCIENT (ERFSF) Luxembourg $14.898B 0.00
ICON (ICLR) Ireland $14.052B 13.52
Medpace Holdings (MEDP) United States $13.301B 35.20
CochLear (CHEOY) Australia $12.977B 0.00
Solventum (SOLV) United States $12.638B 13.04
Viatris (VTRS) United States $12.148B 4.32
Caris Life Sciences,�Inc (CAI) United States $10.748B 0.00
Revvity (RVTY) United States $10.283B 18.12
Avantor (AVTR) United States $8.992B 13.19
Sonic Healthcare (SKHHY) Australia $7.799B 0.00
HealthEquity (HQY) United States $7.608B 33.33
Bausch + Lomb (BLCO) Canada $5.151B 34.64
Sotera Health (SHC) United States $4.687B 26.19
BrightSpring Health Services (BTSG) United States $4.239B 32.34
Amplifon S.p.A (AMFPF) Italy $3.937B 21.83
GeneDx Holdings (WGS) United States $3.711B 84.99
Alignment Healthcare (ALHC) United States $3.196B 0.00
Concentras Parent (CON) United States $2.993B 18.98
Surgery Partners (SGRY) United States $2.926B 36.81
Organon (OGN) United States $2.392B 2.61
KindlyMD (NAKA) United States $2.377B 0.00
Premier (PINC) United States $2.161B 20.04
Progyny (PGNY) United States $1.979B 41.85
Ardent Health (ARDT) United States $1.819B 7.02
PACS (PACS) United States $1.807B 0.00
GoodRx Holdings (GDRX) United States $1.564B 26.47
Pediatrix Medical (MD) United States $1.496B 9.99
Teladoc Health (TDOC) United States $1.368B 0.00
Omada Health (OMDA) $1.343B 0.00
Establishment Labs Holdings (ESTA) $1.230B 0.00
Ryman Healthcare (RYHTY) New Zealand $0.962B 0.00
Embecta (EMBC) United States $0.853B 5.00
AMN Healthcare Services Inc (AMN) United States $0.771B 9.53
CareDx (CDNA) United States $0.707B 13.03
Performant Healthcare (PHLT) United States $0.599B 0.00
QDM (QDMI) Hong Kong, SAR China $0.583B 100.00
Agilon Health (AGL) United States $0.539B 0.00
InnovAge Holding (INNV) United States $0.535B 0.00
Nutex Health (NUTX) United States $0.499B 7.55
Sonida Senior Living (SNDA) United States $0.493B 0.00
Auna S.A (AUNA) Luxembourg $0.466B 6.99
COMPASS Pathways (CMPS) United Kingdom $0.453B 0.00
SBC Medicals (SBC) United States $0.434B 9.50
Enhabit (EHAB) United States $0.406B 26.67
So-Young (SY) China $0.399B 0.00
Oncology Institute (TOI) United States $0.324B 0.00
LifeMD (LFMD) United States $0.304B 0.00
Beauty Health (SKIN) United States $0.260B 0.00
Shoulder Innovations (SI) United States $0.240B 0.00
DocGo (DCGO) United States $0.158B 0.00
Ascend Wellness Holdings (AAWH) United States $0.158B 0.00
Sera Prognostics (SERA) United States $0.107B 0.00
Biodesix (BDSX) United States $0.069B 0.00
NeueHealth (NEUE) United States $0.060B 0.00
IceCure Medical (ICCM) Israel $0.058B 0.00
NeuroOne Medical Technologies (NMTC) United States $0.038B 0.00
Basel Medical Group (BMGL) Singapore $0.036B 0.00
SeaStar Medical Holding (ICU) United States $0.024B 0.00
OSR Holdings (OSRH) United States $0.019B 0.00
Intelligent Bio Solutions (INBS) United States $0.014B 0.00
Co-Diagnostics (CODX) United States $0.013B 0.00
BioNexus Gene Lab (BGLC) $0.010B 0.00
ModivCare (MODV) United States $0.006B 0.00
XWELL (XWEL) United States $0.006B 0.00
Pheton Holdings (PTHL) China $0.005B 0.00
INVO Fertility (IVF) United States $0.004B 0.00
Aclarion (ACON) United States $0.004B 0.00
ISpecimen (ISPC) United States $0.004B 0.00
NewGenIvf Group (NIVF) Thailand $0.002B 0.00
Cano Health (CANOQ) United States $0.000B 0.00